What new medications are coming down the pipeline in Obesity Medicine? I explore the latest and greatest in obesity pharmacotherapy with my guest today, Dr. Sean Wharton.
Dr. Wharton is one of the leading Canadian researchers in Obesity Medicine. He is co-lead author of the Canadian Obesity Guidelines and the primary author of many of the clinical trials in bariatric medicine and type 2 diabetes. We discussed what is being studied in Phase 2 and 3 clinical trials in obesity management including:
• Semaglutide (Wegovy/Ozempic)
• Tirzepatide (Mounjaro/Zepbound)
• Retatrutide (GLP1, GIP, glucagon triple analogue)
• Cagrisema (amylin/GLP1 dual analogue)
• Bimagrumab (human monoclonal antibody)
• Cannabinoid-receptor antagonists (CB1)
• Orforglipron
• Oral GLP1 peptides
• Medications taken once monthly
**A small error that Dr. Wharton wanted to correct. The Amgen molecule discussed today is a GIPR antagonist, not a glucagon antagonist.
This week’s show brought to you by FRIDAY’S HEALTH.
If you’re in the USA looking for a healthcare provider and comprehensive obesity medicine program to support you in a science-backed, compassionate way, then check out Fridays Health. Each patient works with a medical provider as well as a team of coaches to pair medical treatment with effective behavioural support. Use code HIGH to get $20 USD off the first month of your membership.
[ Ссылка ]
FIND DR. SEAN WHARTON
Instagram @drseanwharton
Clinical Trials [ Ссылка ]
FOLLOW SASHA
Instagram - [ Ссылка ]
Tiktok - [ Ссылка ]
WORK WITH ME
Join my Weight Loss Coaching Program for women, Best Weight [ Ссылка ]
Recover Strong for Binge Eating - [ Ссылка ]
Ontario OHIP-covered Obesity Medicine [ Ссылка ]
